Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation

  • Martínez Corral, Inés
  • Zhang, Yan
  • Petkova, Milena
  • Ortsäter, Henrik
  • Sjöberg, Sofie
  • Castillo, Sandra D.
  • Brouillard, Pascal
  • Libbrecht, Louis
  • Saur, Dieter
  • Graupera i Garcia-Milà, Mariona
  • Alitalo, Kari
  • Boon, Laurence
  • Vikkula, Miikka
  • Mäkinen, Taija
Lymphatic malformations (LMs) are debilitating vascular anomalies presenting with large cysts (macrocystic) or lesions that infiltrate tissues (microcystic). Cellular mechanisms underlying LM pathology are poorly understood. Here we show that the somatic PIK3CAH1047R mutation, resulting in constitutive activation of the p110α PI3K, underlies both macrocystic and microcystic LMs in human. Using a mouse model of PIK3CAH1047R-driven LM, we demonstrate that both types of malformations arise due to lymphatic endothelial cell (LEC)-autonomous defects, with the developmental timing of p110α activation determining the LM subtype. In the postnatal vasculature, PIK3CAH1047R promotes LEC migration and lymphatic hypersprouting, leading to microcystic LMs that grow progressively in a vascular endothelial growth factor C (VEGF-C)-dependent manner. Combined inhibition of VEGF-C and the PI3K downstream target mTOR using Rapamycin, but neither treatment alone, promotes regression of lesions. The best therapeutic outcome for LM is thus achieved by co-inhibition of the upstream VEGF-C/VEGFR3 and the downstream PI3K/mTOR pathways.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation

  • Martínez Corral, Inés
  • Zhang, Yan
  • Petkova, Milena
  • Ortsäter, Henrik
  • Sjöberg, Sofie
  • Castillo, Sandra D.
  • Brouillard, Pascal
  • Libbrecht, Louis
  • Saur, Dieter
  • Graupera i Garcia-Milà, Mariona
  • Alitalo, Kari
  • Boon, Laurence
  • Vikkula, Miikka
  • Mäkinen, Taija
Lymphatic malformations (LMs) are debilitating vascular anomalies presenting with large cysts (macrocystic) or lesions that infiltrate tissues (microcystic). Cellular mechanisms underlying LM pathology are poorly understood. Here we show that the somatic PIK3CAH1047R mutation, resulting in constitutive activation of the p110α PI3K, underlies both macrocystic and microcystic LMs in human. Using a mouse model of PIK3CAH1047R-driven LM, we demonstrate that both types of malformations arise due to lymphatic endothelial cell (LEC)-autonomous defects, with the developmental timing of p110α activation determining the LM subtype. In the postnatal vasculature, PIK3CAH1047R promotes LEC migration and lymphatic hypersprouting, leading to microcystic LMs that grow progressively in a vascular endothelial growth factor C (VEGF-C)-dependent manner. Combined inhibition of VEGF-C and the PI3K downstream target mTOR using Rapamycin, but neither treatment alone, promotes regression of lesions. The best therapeutic outcome for LM is thus achieved by co-inhibition of the upstream VEGF-C/VEGFR3 and the downstream PI3K/mTOR pathways.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immune-interacting lymphatic endothelial subtype at capillary terminals drives lymphatic malformation

  • Petkova, Milena
  • Kraft, Marle
  • Stritt, Simon
  • Martinez-Corral, Ines
  • Ortsäter, Henrik
  • Vanlandewijck, Michael
  • Jakic, Bojana
  • Baselga Torres, Eulàlia|||0000-0003-1086-8439
  • Castillo, Sandra D.|||0000-0002-7007-3155
  • Graupera, Mariona|||0000-0003-4608-4185
  • Betsholtz, Christer
  • Mäkinen, Taija
Oncogenic mutations in PIK3CA, encoding p110α-PI3K, are a common cause of venous and lymphatic malformations. Vessel type-specific disease pathogenesis is poorly understood, hampering development of efficient therapies. Here, we reveal a new immune-interacting subtype of Ptx3-positive dermal lymphatic capillary endothelial cells (iLECs) that recruit prolymphangiogenic macrophages to promote progressive lymphatic overgrowth. Mouse model of Pik3ca-driven vascular malformations showed that proliferation was induced in both venous and lymphatic ECs but sustained selectively in LECs of advanced lesions. Single-cell transcriptomics identified the iLEC population, residing at lymphatic capillary terminals of normal vasculature, that was expanded in Pik3ca mice. Expression of pro-inflammatory genes, including monocyte/ macrophage chemokine Ccl2, inPik3ca-iLECs was associated with recruitment of VEGF-C-producing macrophages. Macrophage depletion, CCL2 blockade, or anti-inflammatory COX-2 inhibition limited Pik3ca-driven lymphangiogenesis. Thus, targeting the paracrine crosstalk involving iLECs and macrophages provides a new therapeutic opportunity for lymphatic malformations. Identification of iLECs further indicates that peripheral lymphatic vessels not only respond to but also actively orchestrate inflammatory processes.